Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Test Two

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,266 result(s) found for: Test Two. Displaying page 462 of 564.
    «« First « Previous 458  459  460  461  462  463  464  465  466  Next» Last»»
    EudraCT Number: 2012-001767-71 Sponsor Protocol Number: RX-3341-302 Start Date*: 2013-06-20
    Sponsor Name:Melinta Therapeutics, Inc
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL S...
    Medical condition: ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) ES (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002181-23 Sponsor Protocol Number: CL3-20098-076 Start Date*: 2015-12-14
    Sponsor Name:Institut de Recherche International Servier
    Full Title: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depr...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DE (Ongoing) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000905-38 Sponsor Protocol Number: PCYC-1137-CA Start Date*: 2015-12-17
    Sponsor Name:Pharmacyclics LLC
    Full Title: A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in c...
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001659-37 Sponsor Protocol Number: 26061 Start Date*: 2007-06-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase II Study of ZK 219477 in patients with recurrent glioblastoma
    Medical condition: Phase II study of ZK 219477 in patients with recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005327-63 Sponsor Protocol Number: NN7088-4033 Start Date*: 2016-12-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multi-centre, comparative, double blind, randomised cross-over trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pe...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003657-26 Sponsor Protocol Number: ARD10248 Start Date*: 2012-01-16
    Sponsor Name:sanofi aventis recherche et développement
    Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002579-33 Sponsor Protocol Number: EE-301 Start Date*: 2020-03-26
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophag...
    Medical condition: Erosive Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002810-37 Sponsor Protocol Number: RI-01-007 Start Date*: 2020-03-09
    Sponsor Name:Dr. Reddy’s Laboratories S.A.
    Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continu...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002239-11 Sponsor Protocol Number: MYK-491-003 Start Date*: 2019-04-18
    Sponsor Name:MyoKardia Inc.
    Full Title: Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses...
    Medical condition: Heart Failure with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001776-15 Sponsor Protocol Number: MS202202-0002 Start Date*: 2020-11-16
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR...
    Medical condition: left-sided metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002630-32 Sponsor Protocol Number: NN6435-4697 Start Date*: 2021-07-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: Dose response and safety of an oral PCSK9i, NNC0385-0434, in patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk on maximally tolerated statin dose and other lipi...
    Medical condition: Established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk Elevated cholesterol
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.1 10022891 - Investigations 10005425 Blood cholesterol increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003609-24 Sponsor Protocol Number: MB09-C-01-19 Start Date*: 2021-12-30
    Sponsor Name:mAbxience Research S.L.
    Full Title: A randomised, double-blind, parallel, multicentre, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 (proposed denosumab biosimilar)...
    Medical condition: Postmenopausal women diagnosed with osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) BG (Completed) PL (Completed) LV (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000662-38 Sponsor Protocol Number: D419NC00001 Start Date*: 2017-01-18
    Sponsor Name:MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors
    Medical condition: Advanced solid tumor
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) ES (Ongoing) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003228-22 Sponsor Protocol Number: AC16092 Start Date*: 2016-12-14
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
    Medical condition: Osteogenesis imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004811-26 Sponsor Protocol Number: ALK22/ENZ215-DEN2 Start Date*: 2022-02-21
    Sponsor Name:Alkem Laboratories Limited
    Full Title: A Phase 3, Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics and Immunogenicity of Enzene Denosumab (ENZ215) and ...
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prohibited by CA) DK (Completed) ES (Ongoing) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000722-38 Sponsor Protocol Number: 1203-GITCG Start Date*: 2015-05-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
    Medical condition: HER-2 positive, resectable gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER2 positive gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) BE (Completed) NO (Completed) PT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004339-35 Sponsor Protocol Number: AR-301-002 Start Date*: 2019-01-16
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) c...
    Medical condition: Staphylococcus aureus pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035734 Pneumonia staphylococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FR (Completed) LV (Completed) BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004076-34 Sponsor Protocol Number: 7487-CL-0209 Start Date*: 2014-02-27
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005964-15 Sponsor Protocol Number: IMCL CP12-0715 Start Date*: 2010-01-08
    Sponsor Name:IMCLONE LLC
    Full Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Fol...
    Medical condition: Metastatic Gastric Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) CZ (Completed) MT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013094-17 Sponsor Protocol Number: HOVON103AMLLEN Start Date*: 2010-04-13
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years an...
    Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) NO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 458  459  460  461  462  463  464  465  466  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 13:47:04 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA